Using vedolizumab first, before tumor necrosis facor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

A young woman has spoken out about the realities of dating with inflammatory bowel disease (IBD). Caroline Etheridge, 31, ...

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

In an interview with The Tribune, Dr SPS Grover, a general physician, sheds light on the causes of rectal bleeding and the ...

Multiple failings led to a patient with Crohn's disease having a hysterectomy without giving informed consent, an ombudsman ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The real miracle of healing, however, came from chicken noodle soup. Yes! Ginnie made me homemade chicken and noodles, and did it the Iowa way — over mashed potatoes. Oh boy, takes me back to the days ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...

The long-term incidence of MACE, VTE, and malignancies is low among patients with RA or UC receiving filgotinib, though a slight increase was observed among older patients.

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

UnitedHealth Group, Eli Lilly and Company, Walmart, Johnson & Johnson, AbbVie, McKesson, and Boston Scientific are the seven Medical stocks to watch today, according to MarketBeat’s stock screener ...